Affordable Clinical Trials Software rED Cap™ Slated for Launch at Annual BioFlorida Conference

TAMPA, Fla., Oct. 17, 2011 /PRNewswire/ -- BioStat International Inc., (BSI) today announced plans to launch rED Cap, a new web-based electronic data capture (EDC) software system for managing multi-center clinical research trials at the BioFlorida Annual Conference, October 23-25.

"Most clinical trials software is geared towards well-funded industry research," said Maureen Lyden, M.S., President and Chief Executive Officer of BSI, a contract research organization providing biostatistical and clinical data management services for the pharmaceutical and medical device industry. "BSI recognized a void in the market for a well managed and affordable web based data management solution, for smaller cost-conscious organizations. We developed rED Cap to fill that niche. We believe the capabilities of rED Cap together with the strong data management and biostatistical support of BSI can provide quality, cost-effectiveness, and efficiency to any research study."

The rED Cap system design is based on the CDISC Operational Data Model (ODM) (http://www.cdisc.org/site/index.php), and features multiple layouts for eCRFs, powerful data validation capabilities for increased data quality, and an easy and intuitive process for clinical site coordinators to enter data and manage query tasks. It also allows Monitors to keep up to date with source verification and data entry status, and sponsors to view data and custom reports.

rED Cap has extended features, including options for hybrid projects, with both EDC and paper CRF double-key entry, and independent third-party entry into the same database while blinded from other users.

Lyden and team will rollout rED CapTM at BioFlorida October 24 (Booth 2008) and be on hand for demonstrations and questions.

For more information about BSI, please visit www.biostatinc.com or to inquire about its services or for a demonstration of rED Cap Software, please contact Maureen Lyden at 813-979-1619 or [email protected]

SOURCE BioStat International Inc.

 

Suggested Articles

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.

Operation Warp Speed is living up to its name as AstraZeneca is teaming up with IQVIA to boost its R&D for its pandemic shot.